E3 Ubiquitin Ligases: Structures, Biological Functions, Diseases, and Therapy
MedComm · 2025-12 · 6 (12)
DOI: 10.1002/mco2.70528 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 07.12.2025. Verfasst von Haochen Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: The MOE Basic Research and Innovation Center For the Targeted Therapeutics of Solid Tumors, Jiangxi Provincial Key Laboratory of Bioengineering Drugs…. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 581 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Chongqing.
Abstract (Originalsprache)
E3 ubiquitin ligases are pivotal regulators within the ubiquitin–proteasome system, conferring specificity to protein ubiquitination and subsequent degradation, thereby maintaining cellular homeostasis. Their structural diversity allows for the precise control of vital processes, including the cell cycle, immune responses, and signal transduction, across various tissues. Despite their profound influence on physiology, a systematic understanding of how specific E3 ligases contribute to distinct disease pathogenesis and their translational potential remains incomplete. This review systematically delineates the classification and catalytic mechanisms of major E3 ligase families, including RING, HECT, and RBR types, and elaborates their pathological roles in driving carcinogenesis, cardiovascular remodeling, autoimmune dysregulation, metabolic syndrome, and neurodegenerative aggregation. We further synthesize recent advances in therapeutic modalities, from small‐molecule inhibitors targeting ligases like MDM2 to novel strategies in targeted protein degradation, notably proteolysis‐targeting chimeras (PROTACs) that hijack E3 machinery. By integrating mechanistic insights with emerging therapeutic landscapes, this work underscores the central role of E3 ligases in human diseases and provides a strategic framework for developing next‐generation, mechanism‐based therapeutics.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The MOE Basic Research and Innovation Center For the Targeted Therapeutics of Solid Tumors, Jiangxi Provincial Key Laboratory of Bioengineering Drugs, Institute of Translational Medicine, Jiangxi Medical College Nanchan…
- The Queen Mary School, Jiangxi Medical College Nanchang University Nanchang China.
- Chongqing Research Institute Nanchang University Chongqing China.
- Department of Dental General and Emergency, Jiangxi Province Key Laboratory of Oral Biomedicine, Jiangxi Province Clinical Research Center for Oral Diseases, The Affiliated Stomatological Hospital, Jiangxi Medical Colle…
- Department of Hematology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital Sichuan University Chengdu China.
ORCID-Profile: Jing Guo, Xuan Huang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Chongqing
Zitieren
APA
Wang, H., Peng, J., Li, H., Lan, Y., Guo, J., Qiu, Q., & Huang, X. (2025). E3 Ubiquitin Ligases: Structures, Biological Functions, Diseases, and Therapy. MedComm, 6(12). https://doi.org/10.1002/mco2.70528
Vancouver
Wang H, Peng J, Li H, Lan Y, Guo J, Qiu Q, et al. E3 Ubiquitin Ligases: Structures, Biological Functions, Diseases, and Therapy. MedComm. 2025;6(12). doi:10.1002/mco2.70528
BibTeX
@article{Wang2025,
author = {Wang, Haochen and Peng, Junbo and Li, Hongchan and Lan, Yuzhe and Guo, Jing and Qiu, Qiang and Huang, Xuan},
title = {E3 Ubiquitin Ligases: Structures, Biological Functions, Diseases, and Therapy},
journal = {MedComm},
year = {2025},
volume = {6},
number = {12},
doi = {10.1002/mco2.70528}
}
EUVIMED